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Background: Inhibitor of DNA binding/Differentiation 1 (ID1) is a helix loop helix transcription factor that lacks
the basic DNA binding domain. Over-expression of ID1 has been correlated with a variety of human cancers; our
earlier studies had shown that reported ID1 is induced by nicotine or EGF stimulation of non-small cell lung cancer
(NSCLC) cells and its down regulation abrogates cell proliferation, invasion and migration. Here we made attempts
to identify downstream targets of ID1 that mediate these effects.
Methods: A microarray analysis was done on two different NSCLC cell lines (A549 and H1650) that were
transfected with a siRNA to ID1 or a control, non-targeting siRNA. Cells were stimulated with nicotine and genes
that were differentially expressed upon nicotine stimulation and ID1 depletion were analyzed to identify potential
downstream targets of ID1. The prospective role of the identified genes was validated by RT-PCR. Additional
functional assays were conducted to assess the role of these genes in nicotine induced proliferation, invasion and
migration. Experiments were also conducted to elucidate the role of ID1, which does not bind to DNA directly,
affects the expression of these genes at transcriptional level.
Results: A microarray analysis showed multiple genes are affected by the depletion of ID1; we focused on two of
them: Stathmin-like3 (STMN3), a microtubule destabilizing protein, and GSPT1, a protein involved in translation
termination; these proteins were induced by both nicotine and EGF in an ID1 dependent fashion. Overexpression of
ID1 in two different cell lines induced STMN3 and GSPT1 at the transcriptional level, while depletion of ID1 reduced
their expression. STMN3 and GSPT1 were found to facilitate the proliferation, invasion and migration of NSCLC cells
in response to nAChR activation. Attempts made to assess how ID1, which is a transcriptional repressor, induces
these genes showed that ID1 down regulates the expression of two transcriptional co-repressors, NRSF and ZBP89,
involved in the repression of these genes.
Conclusions: Collectively, our data suggests that nicotine and EGF induce genes such as STMN3 and GSPT1 to
promote the proliferation, invasion and migration of NSCLC, thus enhancing their tumorigenic properties. These
studies thus reveal a central role for ID1 and its downstream targets in facilitating lung cancer progression.
Keywords: ID1, ZBP89, NRSF, Cell proliferation, Transcriptional repression* Correspondence: Srikumar.Chellappan@moffitt.org
†Equal contributors
1Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research
Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
Full list of author information is available at the end of the article
© 2014 Nair et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Nair et al. Molecular Cancer 2014, 13:173 Page 2 of 15
http://www.molecular-cancer.com/content/13/1/173Introduction
Lung cancer is one of the leading causes of cancer-
related deaths worldwide [1] and chemotherapy with
cytotoxic agents has been the mainstay of treatment for
advanced lung cancer [2]. However, the efficacy of these
agents is quite limited, and they have severe adverse
effects. More recently, therapies that specifically target
factors involved in the development and progression of
lung cancer have shown promising efficacy [3]. Greater
than 85% of all lung cancer cases occur among people
who are either current or former tobacco smokers [4].
Epidemiological studies clearly establish cigarette smoking
as the major cause of lung cancer, as well as cancers of the
pancreas, bladder and other organs [5]. It is estimated that
about 90% of male lung cancer deaths and 75% of female
lung cancer deaths in the United States each year are
caused by smoking [6].
Nicotine, the major addictive component of cigarette
smoke is not a carcinogen by itself and cannot initiate
tumorigenesis in humans and rodents [7]; but many of
the carcinogens in tobacco smoke are derivatives of
nicotine. The addictive effects of nicotine are mediated
through pentameric nicotinic acetylcholine receptors
(nAChRs) that are expressed on neurons; nAChRs are
also expressed on muscles, neuromuscular junctions as
well as a variety of non-neuronal tissues [8]. Several
studies have shown that activation of nAChRs on non-
neuronal cells can induce proliferation and that nicotine
has strong mitogenic effects [9,10]. Nicotine was found
to induce cell proliferation in a Src dependent pathway,
that was dependent on the scaffolding proteins β-arrestin-
1 and E2F1 transcription factor [9]. Earlier studies had
also established that nicotine could induce angiogenesis,
raising the possibility that nicotine can affect the biology
of vasculature; indeed, smoking has been correlated with
multiple cardiovascular diseases [11]. The ability of nico-
tine to induce cell proliferation and angiogenesis indicated
that it might have tumor promoting functions and our
earlier studies showed that exposure of cells to nicotine
induced epithelial-mesenchymal transition and promoted
cell invasion and migration [12]. Further, nicotine was
found to promote the growth and metastasis of lung and
pancreatic cancers in mouse xenograft models, suggesting
that nicotine can promote the growth and metastasis of
tumors already initiated by tobacco carcinogens [13,14].
The two most commonly mutated oncogenes in lung
cancer encode the epidermal growth factor receptor
(EGFR) and K-Ras [15]. EGFR kinase domain mutations
are prevalent in lung cancers in non-smokers and have
been established as valid predictors of increased sensitiv-
ity to EGFR kinase inhibitors [16]. EGFR has become an
important therapeutic target for the treatment of lung
cancer especially in non-smokers, since more than 60%
of NSCLCs express EGFR [17]. On the other hand,K-Ras mutations in lung cancer are correlated with to-
bacco use and K-Ras gene is known to be mutated by
tobacco-specific nitrosamines. Given that K-Ras mutations
and EGFR mutations give rise to lung adenocarcinomas as
well as squamous cell carcinomas, we made attempts to
identify any common downstream effectors of these genes.
Our earlier studies showed that the ID1 gene is a down-
stream mediator of both K-Ras and EGFR signaling, and
that ID1 can facilitate cell proliferation, invasion and
migration [18]. ID1 is a member of the helix-loop-helix
protein family and is expressed in a variety of tumor types
[19,20]; increased expression of ID1 has been shown
to be associated with decreased cell differentiation and
enhanced cell proliferation, angiogenesis and metastasis of
various cancers, including lung cancer [21,22]. ID1 exerts
its function by acting as dominant negative transcriptional
repressors of bHLH factors [23]; we found that ID1 is up
regulated in response to nicotine and EGF via nAChR and
EGFR in various lung cancer cell lines [18]. In this current
paper we have identified STMN3 (Stathmin like 3) and
GSPT1 (G1 to S phase transition) proteins to be major
downstream targets of ID1 in NSCLC.
STMN3 is a microtubule destabilizing protein belonging
to the stathmin family of phosphoproteins, along with
stathmin like 2 superior cervical ganglion 10; SCG10) and
stathmin-like 4 (RB3 with two splice variants, RB3′ and
RB3′′). Co-expression of STMN3 and stathmin induced
cell proliferation, migration, and matrix invasion in adeno-
carcinoma as well as squamous cell carcinoma tissues and
reduced stathmin and STMN3 levels affected cell morph-
ology and is associated with a less malignant phenotype
[24]. Tumor cell growth, survival, and dissemination par-
ticularly depend on highly efficient turnover of the micro-
tubule network which contributes to cellular processes
such as cell division and migration. Several factors have
been identified which facilitate dynamic microtubule
instability in cancer cells, and the modulation of micro-
tubule dynamics represents a promising therapeutic
strategy.
Another protein known as GSPT1 also appears to play a
major role in mediating ID1 function. Eukaryotic release
factor 3(eRF3) or GSPT1 is a GTPase that associates with
eRF1 in a complex mediates that translation termination.
Apart from its role in the translation termination, GSPT1
has been shown to play several roles in critical cellular
processes such as cell cycle regulation, cytoskeleton orga-
nization and apoptosis [25]. It has been shown recently
that translation termination factors are also involved in
cancer development and that components of the transla-
tion machinery that are deregulated in cancer cells. We
find that GSPT1 is up regulated upon nicotine stimula-
tion, in an ID1 dependent manner, similar to STMN3.
The results presented here show that STMN3 and GSPT1
are induced by nicotine and EGF in multiple NSCLC cell
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vented their induction. Further, GSPT1 and STMN3
were necessary for ID1 to promote cell proliferation and
invasion. We also present data that suggests ID1, which is
a transcriptional repressor, induces GSPT1 and STMN3 at
the transcriptional level, through the down regulation of
transcriptional repressors NRSF and ZBP89. Thus, the
studies presented here identify novel pathways involved in
the proliferation and invasion of non-small cell lung
cancer cells and opens up new avenues to combat this
disease.
Results
STMN3 and GSPT1 are ID1 regulated genes
Previously our lab had shown that stimulation of
NSCLC cells with nicotine or EGF could lead to the
induction of the ID1 transcription factor, which facili-
tated the proliferation, invasion and migration of cells
[18]. Attempts were made to elucidate the downstream
molecular targets of ID1 that mediate these functional
effects, since ID1 is a transcriptional repressor that does
not bind to DNA. A549 cells were transiently transfected
with ID1 siRNA or a non-targeting control siRNA,
serum starved for 24 hours and stimulated with 1 μM
nicotine or 100 ng/ml EGF for 18 hours. The serum
starvation step was to reduce background signaling
events mediated by growth factors present in the serum,
which could mask the effects of nicotine and EGF. RNA
prepared from these cells after treatment were subjected
to microarray analysis. A list of genes that were up
regulated or down regulated upon nicotine stimula-
tion of A549 cells, or A549 cells depleted of ID1 is listed
(Additional file 1: Tables S1 & S2). Comparing genes that
were up regulated by nicotine in A549 cells but were not
induced when ID1 was depleted identified multiple genes,
raising the possibility that these genes are induced by
nicotine in an ID1 dependent manner, and are probably
mediators of ID1 function. ID1 itself was induced by nico-
tine as expected; in this study we focused on STMN3 and
GSPT1, since they were affected by both nicotine and
EGF (data not shown).
RT-PCR was performed to confirm the induction of
STMN3 and GSPT1 by nicotine and EGF in A549
(Figure 1A, B) and H1650 (Figure 1C, D) cells. Both
STMN3 and GSPT1 were induced by 1 μM nicotine and
100 ng/ml EGF in non-targeting control siRNA trans-
fected cells. As can be seen, the induction by both the
agents was abolished when ID1 was depleted from the
cells by siRNA transfection. This data validates the micro-
array analysis and suggests a role for ID1 in the upregula-
tion of these genes. Additionally, the upregulation of
STMN3 and GSPTI proteins in response to nicotine and
EGF in A549 & H1650 cells were verified by western blot-
ting; in agreement with the RT-PCR results, nicotine andEGF could induce STMN3 and GSPT1 proteins in both
A549 (Figure 1E) and H1650 (Figure 1F) cells; there was
no induction in ID1 siRNA transfected cells, showing a
definite role for ID1 in mediating the induction of these
genes in response to nicotine and EGF.
STMN3 and GSPT1 are induced by Nicotine and EGF
Since RT-PCR experiments showed that the two genes
were induced by nicotine and EGF at the RNA level,
immunofluorescence experiments were conducted to
assess whether this correlated with an increase in pro-
tein levels as well. A549 and H1650 cells were serum
starved for 24 hours and stimulated with 1 μM nicotine
and 100 ng/ml EGF for 24 or 48 hours and the expres-
sion of STMN3 and GSPT1 was examined by immuno-
fluorescence. It was found that STMN3 was distributed
in the cytoplasm and its levels were elevated in response
to nicotine or EGF stimulation. GSPT1 showed a nuclear
localization and was induced by both EGF as well as nico-
tine (Figure 2). The results are quantified in Additional
file 1: Figure S1. This result suggests that both nicotine
and EGF can induce STMN3 and GSPT1 at the protein
level as well; the induction is probably a transcriptional
event, given the RT-PCR results.
Down regulation of STMN3 and GSPT1 inhibits Nicotine
and EGF induced proliferation
Since depletion of ID1 prevented proliferation induced
by nicotine or EGF [18], attempts were made to assess
whether STMN3 and GSTP1 contributed this process.
Towards this purpose STMN3 and GSPT1 were depleted
in A549 and H1650 cells by siRNA transfection; a non-
targeting siRNA was used as control. RT-PCR experi-
ments showed that basal levels of both STMN3 and
GSPT1 were down regulated by the siRNA; further, siRNA
transfection abrogated their induction by nicotine or EGF
in both A549 and H1650 cells (Additional file 1: Figure S2).
To assess the role of these proteins in cell proliferation, the
siRNA transfected cells were serum starved for 24 hours and
subsequently stimulated with 1 μM nicotine or 100 ng/ml
EGF for 18 hours. Stimulation of cells transfected with
the non-targeting control siRNA with nicotine or EGF led
to a robust incorporation of BrdU suggesting S-phase
entry; in contrast, BrdU incorporation was greatly reduced
in cells transfected with siRNAs to STMN3 or GSPT1
(Figure 3A-3D). This suggests that STMN3 and GSPT1
play a major role in nicotine and EGF-mediated induction
of cell proliferation.
Down regulation of STMN3 and GSPT1 abrogates the
invasive capacity of cells
Our earlier studies had shown that nicotine stimulation of
cells could enhance the invasive properties of cells, and
could promote metastasis in mice [13]. Boyden chamber
Figure 1 Nicotine and EGF induces expression of STMN3 and GSPT1 in NSCLC cell lines; and depletion of ID1 by siRNA reduced this
induction. (A & B) RT-PCR showing significant fold reduction in STMN3 and GSPT1 in A549. (C & D) Similar results were obtained in H1650 cells,
(E) Western blot analysis showing the upregulation of STMN3 & GSPT1 proteins by nicotine and EGF in non-targeting control siRNA cells and
absence of induction in ID1 depleted A549 cells, (F) similar results were obtained in H1650 cells. The above data are expressed as mean ± SD of
three independent experiments. *represents p value of <0.05; **represents p value of <0.02.
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and GSPT1 affected the invasive property of A549 and
H1650 cells. Cells were transiently transfected with 100
pmol of a non-targeting control siRNA or siRNAs to
STMN3 or GSPT1, serum starved for 24 hours, and sub-
sequently stimulated with 1 μM nicotine or 100 ng/ml
EGF for 24 hours. Boyden chamber assays showed that
cells transfected with the non-targeting control siRNA
invaded through the collagen and Matrigel-coated filters
upon nicotine and EGF stimulation (Figure 3E-3H).
In contrast, the invasion was greatly inhibited in cellstransfected with STMN3 and GSPT1 siRNAs, suggest-
ing that invasion induced by these agents requires
STMN3 and GSPT1. Representative images of the Boyden
Chamber assay in A549 and H1650 shows the loss of inva-
sive activity upon STMN3 & GSPT1 depletion (Additional
file 1: Figure S3).
Down regulation of STMN3 and GSPT1 abrogates
migratory ability of cells
We next examined whether STMN3 and GSPT1 played
a role in nicotine induced cell migration, using wound-
Figure 2 Immunofluorescence experiments confirming the upregulation of STMN3 and GSPT1 in A549 and H1650 cells exposed to
nicotine and EGF as compared to serum starved cells. (A) A549 cells fixed and stained showing increased cytosolic expression of STMN3 and
nuclear localization of GSPT1, 400X magnification (B) similar findings observed in the H1650 cells fixed and stained showing increased cytosolic
expression of STMN3 and nuclear localization of GSPT1, 400X magnification. Three independent experiments were done and analyses were based
on multiple fields.
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cells were transfected with siRNAs to STMN3 and GSPT1
or a non-targeting control siRNA and grown to 80-90%
confluency on 35 mm dishes, and a wound-healing assaywas conducted to assess cell migration in response to
nicotine or EGF stimulation. It was found that non-
targeting control siRNA transfected cells migrated into
the wound in response to EGF or nicotine stimulation. At
Figure 3 Depletion of STMN3 and GSPT1 by siRNA transfection in NSCLC cells significantly reduces nicotine and EGF induced cell
proliferation and invasion. (A & B) showing reduced cell proliferation of A549 cells in response to nicotine and EGF, when STMN3 and GSPT1
are depleted, (C & D) Similar results were obtained in H1650 cells. The results are representative of three independent experiments done in
duplicates. (E & F) Depletion of STMN3 and GSPT1 inhibits the invasion of A549 cells upon stimulation with nicotine and EGF as compared to
serum starved cells, (G & H) similar inhibition was observed in the H1650 cells. The above data are expressed as mean ± SD of three independent
experiments. *represents p value <0.05 and **represents p value < 0.0005.
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GSPT1 showed significantly reduced migration, especially
in response to nicotine (Figure 4A & B). There was
minimal migration in response to EGF. This result
suggests that STMN3 and GSPT1 play a role in the
migratory capacity of cells, in addition to proliferation
and invasion.STMN3 and GSPT1 are elevated in cells stably over
expressing ID1
Since we found that depletion of ID1 could reduce the
levels of STMN3 and GSPT1 messages, we examined
whether over-expression of ID1 elevates these genes in
two clones of A549 that stably over-expressed ID1 protein.
Over-expression of ID1 was confirmed by both RT-PCR
Figure 4 Depletion of STMN3 and GSPT1 inhibits migration of NSCLC cells, as seen in wound-healing assays. (A) Depletion of STMN3
and GSPT1 by transient transfection of 100 pmol of respective siRNA into A549 cells significantly reduces nicotine and EGF induced cell migration,
(B) similar results were obtained in H1650 cells.
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experiments. Both experiments showed that levels of
STMN3 and GSPT1 messages and protein were ele-
vated in the stable clones compared to the parental
cells. This experiment provides additional support to
the finding that ID1 can induce STMN3 and GSPT1 in
NSCLC cells.
ID1 induces the promoters of STMN3 and GSPT1
Experiments were conducted to assess whether ID1
could induce the STMN3 and GSPT1 promoters. For
this purpose, approximately 2000 bp promoter regions
of STMN3 and GSPT1 were cloned in pGL3 basic
vector. A549 and H1650 cells were transiently trans-
fected with luciferase reporters driven by STMN3 and
GSPT1 promoters. Co-transfection of increasing amounts
of ID1 enhanced the expression of the two promoters
in both the cell lines in a dose-dependent manner
(Figure 5C & D). There was approximately a 3 fold
increase in the luciferase activity using as low as 1 μg
of STMN3 and GSPT1 promoter and 2 μg ID1. These
results suggest that ID1 induces the expression of the
STMN3 and GSPT1 at the transcriptional level.Figure 5 Stable transfection confirming the ID1 overexpression in A5
and depletion of ID1 elevates the expression of STMN3 & GSPT1. (A)
GSPT1 in ID1 over expressing clones as compared to the non-targeting con
were also elevated as seen in a western blot in the selected clones using G
induce STMN3-luciferase and GSPT1-luciferase promoters in a dose depend
and H1650 cells as shown in the graph.ID1 regulates STMN3 and GSPT1 expression by repressing
ZBP89 and NRSF
ID1 is an established transcriptional repressor, while and
we find that it induces the transcription of STMN3 and
GSPT1. Given this observation attempts were made to as-
sess how ID1, which is a transcriptional repressor, induces
gene expression. One potential mechanism is through the
repression of transcriptional co-repressors. Our earlier
studies had shown that ID1 could induce the mesenchy-
mal genes fibronectin and vimentin through the mediation
of the transcriptional repressor, ZBP89 [18]. Promoter
analysis revealed several putative binding sites for the
previously reported repressor ZBP89 on the proximal pro-
moter of STMN3. Besides that, binding sites for another
transcriptional repressor, NRSF, were also found on the
promoter region of STMN3 as reported elsewhere [26].
Given this background, we performed a RT-PCR experi-
ment to determine the role of ZBP89 and NRSF in the
induction of GSPT1 and STMN3. A549 and H1650 cells
were transfected with non-targeting control siRNA,
ZBP89 siRNA and NRSF siRNA; it was found that deple-
tion of ZBP89 and NRSF induced an upregulation of
STMN3 and GSPT1 (Figure 6A & B). This result suggests49 cell and dose dependent induction of STMN3 & GSPT1 by ID1
The overexpressing (OE) clones showed upregulation of STMN3 and
trol vector (pcDNA3) as observed by RT-PCR, (B) ID1 protein levels
418 resistance confirming the ID1 over-expression, (C) ID1 could
ent manner in transient transfection experiments in A549 cells, (D)
Figure 6 Role of NRSF and ZBP89 in modulating the expression of STMN3 and GSPT1. (A) Depletion of NRSF or ZBP89 leads to the
induction of STMN3 and GSPT1 in A549 cells, as seen by a RT-PCR experiment. (B) Similar results were obtained in H1650 cells. (C) Western blot
showing the induction of ZBP89 and NRSF upon depletion of ID1 in A549 cells; there was a corresponding decrease in the levels of STMN3 and
GSPT1. (D) A western blot on H1650 cells showed essentially identical results.
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pressing ZBP89 and NRSF. Western blots were conducted
on lysates from A549 cells and H1650 cells that were
transfected with a control siRNA or an ID1 siRNA, and
stimulated with nicotine or EGF. It was found that deple-
tion of ID1 led to an increase in the levels of NRSF and
ZBP89 (Figure 6C, D). Western blotting of the same
lysates showed a corresponding decrease in STMN3 and
GSPT1 levels, further supporting the notion that ID1
induces STMN3 and GSPT1 by repressing the levels of
ZBP89 and NRSF. Depletion of ID1 led to an induction of
ZBP89 and NRSF as seen by RT-PCR (Additional file 1:
Figure S4), and suppressed cell proliferation as seen by a
MTTAssay.
To further confirm the role of NRSF and ZBP89 in the
regulation of STMN3 and GSPT1, transient transfection
experiments were conducted, using STMN3 and GSPT1
promoter-luciferase constructs in cells transfected with a
non-targeting control siRNA or si RNAs to NRSF or
ZBP89. When NRSF was depleted, there was an increased
transcription of STMN3 promoter in A549 (Figure 7A) or
H1650 (Figure 7C), while depletion of ZBP89 resulted inincreased transcription of GSPT1 promoter in A549
(Figure 7B) and H1650 (Figure 7D) cells). Similarly,
there was no further induction of STMN3 and GSPT1
when ID1 was co-transfected with NRSF siRNA or ZBP89
siRNA, suggesting that NRSF and ZBP89 are the main
facilitators of ID1 mediated induction of STMN3 and
GSPT1 expression.
Discussion
Nicotine, the main addictive component of the cigarette
smoke, can promote the growth and metastasis of lung
cancers by modulating various signaling cascades. One
downstream mediator of nicotine functions is the bHLH
transcription factor, ID1 [18], which is known to promote
oncogenesis by enhancing cell proliferation and inhibiting
differentiation. The fact that both nicotine and EGF could
induce the expression of ID1 in a Src-dependent manner
raises the possibility that ID1 might be contributing to the
genesis of lung cancers in both smokers and nonsmokers.
These findings are supported by the fact that ID1 is often
elevated in a variety of tumors, many of which are not
correlated with smoking. Our results showing the tumor
Figure 7 Depletion of NRSF or ZBP89 leads to an induction of STMN3 and GSPT1. (A) A transient transfection experiment on A549 cells
showing that depletion of NRSF leads to an induction of STMN3-Luc, comparable to the induction by co-transfecting ID1; there was no further
induction when ID1 was co-transfected with NRSF siRNA. (B) In a similar co-transfection experiment on A549 cells, depletion of ZBP89 led to an
induction of GSPT1, and there was no further induction when ID1 was co-transfected. (C) and (D) show similar results that were obtained in
H1650 cells. The above data are all expressed as mean ± SD of three independent experiments. *represents p value of <0.05; **represents
p value of <0.02.
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recent report showing that ID1 promotes NSCLC cell
migration [21].
The finding that STMN3 gene is a downstream target
of the ID1, and responds to signaling from nAChRs and
EGFR in lung cancer cells is relevant for various reasons.
Stathmin (STMN) is an evolutionarily conserved, ubiqui-
tously expressed, tubulin-binding protein that has been
associated with cell proliferation and differentiation. It is a
member of a phosphoprotein family that also includes
Stathmin-like 2 (STMN2), Stathmin-like 3 and Stathmin-
like 4 (STMN4). In addition to its well-known role in cell
division, STMN3 is also involved in other microtubule-
dependent processes such as cell motility [27,28]. STMN3
is over-expressed in adenocarcinoma as well as squamous
cell carcinoma (SCC) samples and STMN3 promoted cell
proliferation, migration, and invasion [24]. In addition,
reduced STMN3 level affected cell morphology and was
associated with a less malignant phenotype. The substan-
tial expression of STMN3 in most tissues point out a
novel function for this protein outside the nervous system
and raises the possibility that modulation of STMN3
could promote nicotine mediated induction of non-small
cell lung cancer progression and metastasis. In addition to
post-translational modifications, STMN3 is regulated bytranscription factors such as Egr1, p53 and members of
the E2F family [29]. Another study demonstrated that
STMN3 is required to maintain cell–cell adhesion in
MCF-7 cells and its down-regulation contributes to the
loss of epithelial morphology [30]. Over-expression of
stathmin family members has been reported in hepatocel-
lular carcinoma [31], sarcoma [32], and lung adenocarcin-
omas [33] and poorly differentiated tumors of the breast
and ovaries express higher levels of stathmin than more
differentiated and less proliferative tumors [27]. Recent
studies have also revealed STMN3 contributes to chromo-
some instability leading to aneuploidy, cell migration and
chemo-resistance [34,35], which could be due to the regu-
lation of microtubule stability by STMN3. These studies
suggest that STMN3 potentially contributes to tumor
development and progression through the regulation of
multiple cellular processes and is probably a good target
for the development of therapeutic agents.
It is now widely recognized that translation factors are
involved in cancer development and that components of
the translation machinery that are deregulated in cancer
cells may become targets for cancer therapy. The eukar-
yotic Release Factor 3 (eRF3) is a GTPase that associates
with eRF1 in a complex that mediates translation termin-
ation. In humans, eRF3 has two distinct isoforms, eRF3a
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eRF3b/GSPT2 gene [36,37]. The N-terminal domain of
GSPT1 has been shown to participate in essential protein
interactions necessary for different functions such as the
formation of the translation termination complex [38].
Apart from its pivotal role in translation, the N-terminal
domain of GSPT1 was also reported to interact with
various proteins with different biological functions
and also to act as a regulator of apoptosis [39]. GSPT1
mRNA is abundant in all tissues and its level varies during
the cell cycle, whereas GSPT2 mRNA is poorly expressed
in most mouse tissues tested, except in brain [40]. It has
been previously reported that GSPT1 mRNA level is
increased in 70% of the intestinal type gastric tumors [41]
and strongly decreased during human chondrocyte differ-
entiation [42]. Understanding GSPT1 gene regulation and
its relation with cell cycle progression and cellular pro-
liferation may have prognostic value and potential
therapeutic applications.
An additional interesting observation made in these
studies is that the transcriptional repressors NRSF and
ZBP89 are modulated by ID1 to effect the induction of
STMN3 and GSPT1. NRSF, or neuron-restrictive silencer
factor, is known to bind to neuron-restrictive silencer ele-
ments to repress transcription of various genes involved
in neuronal functions; it has also been shown to have
functions in non-neuronal cells and cancers of various
organs. A role for this factor has been proposed in various
neuronal disorders, including Huntington’s Disease. It is
intriguing that multiple genes and transcriptional co-
factors that are predominantly shown to play a role in
neuronal functions are altered in NSCLC cells. It is pos-
sible that these genes as well as transcription factors
respond to nAChRs, which are expressed at high levels in
neurons and neuromuscular junctions. Thus, the involve-
ment of such proteins might be indicative of a generalized
function for them downstream of nAChRs, or it is possible
that they also contribute to NSCLC. Earlier studies from
our lab has shown that expression of vimentin and fibro-
nectin is regulated by ID1 at transcriptional level, by down
regulating ZBP89, which is a transcriptional repressor of
vimentin and fibronectin [43,44]. These studies report
ZBP89 regulating multiple aspects of tumor development
including cell proliferation and apoptosis. Linking ZBP89
to ID1 presents an interesting scenario where a trans-
criptional repressor down regulates a second repressor, to
promote the expression of various genes that promote cell
proliferation and invasion.
As mentioned earlier, ID1’s proliferative and anti-apop-
totic functions have been correlated with the onset and
progression of a variety of human tumors, including those
of the mammary gland and pancreas [45,46], and its over
expression is significantly associated with increased tumor
angiogenesis and a worse prognosis in these cancers [47].Taken together, our studies strongly suggest that nicotine
and EGF might be promoting the proliferation, invasion
and migration of non-small cell lung cancer cells via up
regulating ID1, which leads to the induction of down-
stream proteins like STMN3 and GSPT1 through the
involvement of transcriptional repressors like ZBP89 and
NRSF. These proteins might turn out to good targets for
combating NSCLC.
Conclusions
In summary, our studies show that ID1 plays a signifi-
cant role in promoting cell proliferation, invasion and
migration downstream of nAChRs and EGFR. These
tumor-promoting functions of ID1 appear to be brought
about by STMN3 and GSPT1, which are up regulated by
ID1. These studies also presents an interesting scenario
where ID1, which is a transcriptional repressor, induces
downstream targets by repressing established transcrip-
tional repressors like NRSF and ZBP89. Our results raise
the possibility that alterations in these gene regulatory
pathways lead to the genesis and progression of NSCLC
and targeting these regulatory molecules might be a
viable strategy to combat NSCLC.
Materials and methods
Cell lines and reagents
The two human NSCLC cell lines used in this study
were A549 (K-Ras mutant) and H1650 (EGFR mutant)
obtained from ATCC. These cell lines were maintained
in Ham’s F-12 K and RPMI-1640 (Mediatech Cellgro,
USA) supplemented with 10% FBS (Mediatech Cellgro,
USA). Nicotine (Sigma, USA) and EGF (Sigma, USA)
used in the studies were 1 μM and 100 ng/ml respectively
for 18–24 hours depending on the experiment. The cells
were grown to 70% confluency in complete medium with
serum for 24 hours and rendered quiescent by serum
starvation for 48 hours and stimulated with nicotine and
EGF for 18–24 hours for analysis.
Microarray data analysis
A549 and H1650 cells were transfected with a siRNA to
ID1 or a control, non-targeting siRNA, subjected to serum
starvation for 48 hours and subsequently stimulated with
nicotine for 18 hours. Total RNA extracted from the
samples were used to generate cDNA targets, which
were hybridized to Human Genome U133A plus 2.0 oligo-
nucleotide probe arrays (Affymetrix, Santa Clara, CA)
according to standard protocols. Raw data was processed
by log2 transformation of the expression values, and the
mean center expression level for each gene was deter-
mined. We looked for genes that were over- or under
expressed upon ID1 depletion, whose expression was al-
tered at least two fold. Genes that were differentially
expressed upon nicotine stimulation and ID1 depletion
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been deposited in NCBI’s Gene Expression Omnibus
through GEO Series accession number GSE38944.
siRNA transfections and real time PCR
The siRNA oligonucleotides for ID1 (SC-29356), STMN3
(SC-76459) and GSPT1 (SC-93210) were purchased from
Santa Cruz Biotechnology. A non-targeting siRNA
was used as the control. A549 and H1650 cells were
grown in 60 mm dishes and transfected either with
control siRNA (100 pmol) or target siRNA (100 pmol)
using Oligofectamine (Invitrogen, CA) in as per the man-
ufacturer’s recommendations. The total RNA was isolated
using the RNeasy kit (Qiagen, CA). Levels of ID1 mRNA,
STMN3 mRNA and GSPT1 mRNA were analyzed by
quantitative reverse transcription PCR performed on a
Bio-Rad iCycler. Data were normalized to GAPDH RNA,
and fold change was represented as 2-ΔΔct. The primers
designed for qRT-PCR used for amplifying ID1, STMN3
and GSPT1 are shown (Additional file 1: Table S3).
Generation of stable cell lines
A549 cells that stably overexpress ID1 were generated by
transfecting A549 cells with the ID1 expression plasmid
construct in pcDNA3 and selecting for G418 resistance.
A549 cells transfected with empty vector (pcDNA3) were
used as control.
Lysate preparation and Western blots
Lysates from A549 & H1650 cells treated with different
agents and transfected (transient or stable) as per the ex-
perimental needs were subjected to NP-40 lysis method.
Lysates from these cells were prepared by NP-40 lysis as
described earlier and 100 μg protein was run on a poly-
acrylamide SDS gel. The proteins were transferred to a
nitrocellulose membrane and immunoblotted with anti-
bodies raised against various proteins. Monoclonal ID1
antibody was purchased from Biocheck, USA (BCH-1;
Cat .no# 195–14), Monoclonal NRSF and ZBP89 anti-
body (Cat.no# SC-374611 & Cat.no# SC-137171), poly-
clonal STMN3 (Cat.no# SC-85907) from Santa Cruz
Biotechnology, polyclonal GSPT1 from proteintech (Cat.
no: 10763-1-AP) and monoclonal antibody to actin was
purchased from Sigma, USA.
Cell proliferation assays
A549 and H1650 cells were plated on poly-D-lysine
coated glass chamber slides at a density of 5,000 cells
per well and transiently transfected with siRNA for ID1,
STMN3 and GSPT1, or a non-targeting control siRNA
(100 pmol) using Oligofectamine reagent (Invitrogen,
USA). Cells were serum starved for 24 hours after
transfection and stimulated with 1 μM nicotine or
100 ng/ml EGF for 18 hours. Cell proliferation was assessedby BrdU incorporation assays using a kit from Roche
Biochemicals, USA. BrdU incorporation was visualized
by microscopy and quantitated by counting 5 fields of
100 cells in triplicate. Data presented is representative
of two independent experiments and presented as the fold
change of BrdU positive cells.
Cell proliferation assay was also measured with MTT
(Thiazolyl Blue Tetrazolium Bromide) after 48 hours of
nicotine treatment. Briefly, cells were plated in 96-well
plates at a density of 7500 cells/well in triplicates. After
nicotine treatment as mentioned above, they were incu-
bated with the 1 mg/mL MTT solution at 37°C for 1 hour.
The reaction was terminated with DMSO that solubilizes
the formazan product formed. Absorbance at 590 nm was
recorded using plate reader.Invasion assays
The invasion of A549 and H1650 cells was measured
using Boyden Chamber assays, as described before [18].
Both the cell lines were subjected to transient transfection
using ID1 siRNA, STMN3 siRNA and GSPT1 siRNA.
After 24 hours of transfection, cells were rendered quies-
cent by serum starvation, and then treated with 1 μM
nicotine or 100 ng/ml EGF for 24 hours. Briefly, the upper
surfaces of the transwell filters were precoated with colla-
gen (100 μg/filter). Matrigel was applied to the upper sur-
face of the filters (50 μg/filter) and dried in a hood. These
filters were placed in Boyden chambers (Costar, USA).
Following treatment with nicotine and EGF for 24 hours,
cells were trypsinized and 20,000 cells were plated in the
upper chamber of the filter in media containing 0.1%
bovine serum albumin (Sigma, USA) and Nicotine or
EGF. Media containing 20% fetal bovine serum was placed
in the lower well as an attractant and the chambers were
incubated at 37°C for 18 hours. The filters were processed
first by fixing them in methanol followed by staining
them with hematoxylin. The cells migrating on the other
side of the filters were quantitated by counting six differ-
ent fields in three independent experiments under 20X
magnification.Wound healing assay
A549 and H1650 transfected with siRNAs to ID1, STMN3
and GSPT1 were grown in a 6-well plate (Falcon Becton
Dickinson, USA). These cells were grown in serum free
media for 24 hours and then washed with 1x Dulbecco’s
Phosphate-buffered saline (MediaTech, USA). The cells
were scratched with a sterilized 200 μl pipette tip in three
separate places in each well and medium containing 1 μM
nicotine, EGF (100 ng/ml) or starving media was added to
the wells. After 24 hours, the wounds were examined for
closure by microscopy and images were taken at 20X
magnification.
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STMN3 and GSPT1 gene sequence was searched using
NCBI Genome database, promoter sequence analysis
was conducted using Ensembl database, the homology of
the cloned STMN3 promoter sequence was confirmed
using NCBI BLAST [48] software and the transcription
factor binding sites were analyzed using MatInspector,
Genomatix software (Genomatix Software GmbH, Munich,
Germany).
Primers were designed to amplify about 2 kb upstream
from the ATG region of the STMN3 and GSPT1 pro-
moters. The PCR primers used were STMN3: forward,
5'- GAC AGA GTC TTG CTG TTT CGC C -3'; reverse,
5'- GAA CTG TCT GTG TGT GTC CTG C -3'); and
GSPT1 forward,5’- GTG GGT GGG TGG GGA GTG
AAA AT-3’; reverse, 5'-GCA GTG TGG CTC ATA
AAG CGC TG-3’ based on the sequence retrieved from
the database of Ensembl. The amplified PCR product was
first cloned into pCR 2.1 TA cloning vector (Invitrogen)
and subsequently sub cloned into pGL3 basic vector
(Promega, USA) to generate the 2 kb reporter constructs.
Transfections and luciferase assays
STMN3 promoter-luciferase and GSPT1 promoter-lucif-
erase constructs were transfected into A549 and H1650
cells using FuGENE HD (Roche Diagnostics, USA). In
brief cells were plated for 24 hours before transfection at
a density of 85,000 cells per well and then transfected
with reporter and expression plasmids as indicated; ID1
a renilla luciferase vector was used as internal control.
After 48 hours, the cells were harvested and luciferase
activities were determined using a microplate lumin-
ometer (Turner luminometer, USA). For each construct,
relative luciferase activity was defined as the mean value
of the firefly luciferase/ Renilla luciferase ratios obtained
from at least three independent experiments. Dual lucif-
erase assay system (Promega, USA) following the manu-
facturer’s protocol and luciferase activity was measured
with a luminometer.
Immunofluorescence
Cells grown on coverslips were washed with PBS, fixed
with 10% buffered formaldehyde in PBS buffer for 15 min
at RT, washed three times with PBS (50 mM Tris,
138 mM NaCl, 2.7 mM KCl, pH 7.6), permeabilized with
Triton X-100 (0.25% v/v in PBS) for 5 min, before being
washed twice and blocked for 1 hour in blocking solution
(PBS containing 10% goat serum and 0.1% Triton X-100).
Coverslips were then, incubated with antibodies anti-
STMN3 (1:200) and anti-GSPT1 (1:200) (ProteinTech,
USA) in a solution of 10% goat serum at RT in a humidi-
fied chamber overnight. After washing three times
with PBS, slides were incubated with Alexa Fluor 488
goat anti-mouse-IgG (1:200, Invitrogen GmbH, Karlsruhe,Germany) in blocking solution for 1 hour. Slides were
then washed again three times before being counter-
stained with DAPI (0.2 μg/ml in water) for 5 min, briefly
washed with PBS, covered with anti-fade mounting
medium (Vectashield, Germany) and placed onto micro-
scope slides. Slides were examined under a Zeiss Axiovert
fluorescence microscope (Carl Zeiss AG, Germany). Nega-
tive controls were performed omitting the primary anti-
bodies. These experiments were replicated three times and
the quantification of the immunofluorescence is shown in
the supplementary figures (Additional file 1: Figure S3).
Statistical analysis
Data were presented as the mean ± SD (standard deviation)
from three independent experiments except where indi-
cated. To assess the statistical significance of differences,
student t-test and of p < 0.05 was considered significant.
Additional file
Additional file 1: Table S1. Partial list of up regulated and down
regulated genes in A549 cells treated with Nicotine. Genes that were up
regulated or down regulated two fold in quiescent A549 upon
stimulation with 1 μM nicotine for 18 hrs. Table S2. Partial list of the
genes downregulated in A549 upon nicotine stimulation when ID1
expression was depleted. Genes that were down regulated two fold or
more in quiescent A549 transfected with 100 pmoles of ID1 siRNA and
stimulated with 1 μM nicotine for 18 hrs. Figure S1. Quantification of
immunofluorescence in A549 & H1650 cells showing the induction of
STMN3 and GSPT1 in response to Nicotine & EGF using integrated
density as the parameter (supporting data for Figure 2). Figure S2. A549
and H1650 cells transfected with STMN3 and GSPT1 siRNA. (A & B)
Transient transfection in A549 or H1650 cells (C, D) using siRNAs shows
significant down regulation of the STMN3 and GSPT1 mRNA. Data
expressed as mean ± SD of three independent experiments. Figure S3.
Depletion of STMN3 and GSPT1 reduces cell invasion in vitro in A549 and
H1650 cells. (A) Depletion of STMN3 and GSPT1 significantly inhibited the
invasion induced by nicotine and EGF in a Boyden-chamber invasion
assay. Cells were fixed and stained with hematoxylin and quantified as in
Figure 3E-3H. Figure S4. Depletion of ID1 by transient transfection up
regulates ZBP89 & NRSF, whereas it abrogates the cell growth & proliferation
in A549 & H1650. RT-PCR showing upregulation of ZBP89 (A), NRSF (B) in
the cells depleted of ID1 (C). (D) Depletion of ID1 in A549 and H1650 cells
significantly reduces nicotine & EGF induced cell proliferation as seen in
BrdU incorporation and viability as seen in MTT assays (E). *represents
p value <0.05 and **represents p value < 0.0005.
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NRSF: Neuron –restrictive silencer factor; ZBP89: Zinc binding protein;
EGFR: Epidermal growth factor receptor.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SC directed the overall study. SN carried out the functional assays with
A549 & H1650 cell lines, performed quantitative RT-PCR, Immunofluorescence,
generation of ID1 overexpressing stable clones, transient and stable transfections
for the promoter –luciferase reporter assay experiments, cloning and construction
of STMN3 promoter for the reporter assays. DP designed primers, cloning and
construction of GSPT1 promoter for the reporter assays and performed transient
transfections followed by luciferase assays, NBS performed the western blot
analysis confirming the upregulation of STMN, GSPT1 & ID1 with response to
Nair et al. Molecular Cancer 2014, 13:173 Page 14 of 15
http://www.molecular-cancer.com/content/13/1/173Nicotine & EGF and downregulation of the same in ID1 depleted cells, MTT &
BrdU assays provided in the supplementary data, SN, NBS & DP contributed to
writing the manuscript, SC corrected and revised the manuscript, SN, DP, NBS &
SC read and approved the final manuscript.
Acknowledgements
This study was supported by the grant CA139612 from the NCI to SPC.
Support of the Core Facilities at the Moffitt Cancer Center is gratefully
acknowledged.
Author details
1Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research
Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. 2Department of
Pediatrics, University of South Florida, 12908 Bruce B. Downs Blvd, Tampa, FL
33612, USA. 3Department of Hematology and Medical Oncology, Icahn
School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1079, New
York, NY 10029, USA.
Received: 18 March 2014 Accepted: 4 July 2014
Published: 16 July 2014
References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin
2013, 63:11–30.
2. Zaric B, Stojsic V, Tepavac A, Sarcev T, Zarogoulidis P, Darwiche K, Tsakiridis
K, Karapantzos I, Kesisis G, Kougioumtzi I, Katsikogiannis N, Machairiotis N,
Stylianaki A, Foroulis CN, Zarogoulidis K, Perin B: Adjuvant chemotherapy
and radiotherapy in the treatment of non-small cell lung cancer (NSCLC).
J Thorac Dis 2013, 5:S371–S377.
3. Binder D, Hegenbarth K: Emerging options for the management of
non-small cell lung cancer. Clin Med Insights Oncol 2013, 7:221–234.
4. Hecht S: Cigarette smoking: cancer risks, carcinogens, and mechanisms.
Langenbeck's Arch Surg 2006, 391:603–613.
5. Hecht SS: Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst
1999, 91:1194–1210.
6. Bunn PA: Worldwide overview of the current status of lung cancer
diagnosis and treatment. Arch Pathol Lab Med 2012, 136:1478–1481.
7. Lerman C, LeSage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL,
Corrigall WA: Translational research in medication development for
nicotine dependence. Nat Rev Drug Discov 2007, 6:746–762.
8. Albuquerque EX, Pereira EFR, Alkondon M, Rogers SW: Mammalian
Nicotinic Acetylcholine receptors: from structure to function. Physiol Rev
2009, 89:73–120.
9. Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E,
Chellappan S: Nicotine induces cell proliferation by beta-arrestin-
mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 2006,
116:2208–2217.
10. Shin VY, Jin HC, Ng EKO, Yu J, Leung WK, Cho CH, Sung JJY: Nicotine and
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2
activity in human gastric cancer cells: involvement of nicotinic acetylcholine
receptor (nAChR) and β-adrenergic receptor signaling pathways. Toxicol
Appl Pharmacol 2008, 233:254–261.
11. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL,
Cooke JP: Nicotine stimulates angiogenesis and promotes tumor growth
and atherosclerosis. Nat Med 2001, 7:833–839.
12. Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, Banerjee S,
Carless M, Kim E, Coppola D, Haura E, Chellappan S: Nicotine induces cell
proliferation, invasion and epithelial-mesenchymal transition in a variety
of human cancer cell lines. Int J Cancer 2009, 124:36–45.
13. Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D, Chellappan S:
Nicotine promotes tumor growth and metastasis in mouse models of
lung cancer. PLoS One 2009, 4:e7524.
14. Trevino JG, Pillai S, Kunigal S, Singh S, Fulp WJ, Centeno BA, Chellappan SP:
Nicotine induces inhibitor of differentiation-1 in a Src-dependent
pathway promoting metastasis and chemoresistance in pancreatic
adenocarcinoma. Neoplasia 2012, 14:1102–1114.
15. Inoue A, Nukiwa T: Gene mutations in lung cancer: promising predictive
factors for the success of molecular therapy. PLoS Med 2005, 2:e13.
16. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese
PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F: EGFR
mutations in non small-cell lung cancer: analysis of a large series ofcases and development of a rapid and sensitive method for diagnostic
screening with potential implications on pharmacologic treatment.
J Clin Oncol 2005, 23:857–865.
17. Van Zandwijk N, Mathy A, Boerrigter L, Ruijter H, Tielen I, de Jong D, Baas P,
Burgers S, Nederlof P: EGFR and KRAS mutations as criteria for treatment
with tyrosine kinase inhibitors: retro- and prospective observations in
non-small-cell lung cancer. Ann Oncol 2007, 18:99–103.
18. Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, Bepler G, Haura E,
Coppola D, Chellappan S: ID1 facilitates the growth and metastasis of
non-small cell lung cancer in response to Nicotinic Acetylcholine
receptor and epidermal growth factor receptor signaling. Mol Cell Biol
2011, 31:3052–3067.
19. Norton JD: ID helix-loop-helix proteins in cell growth, differentiation and
tumorigenesis. J Cell Sci 2000, 113:3897–3905.
20. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM: Id proteins in cell growth
and tumorigenesis. Cancer Cell 2003, 3:525–530.
21. Bhattacharya R, Kowalski J, Larson AR, Brock M, Alani RM: Id1 promotes
tumor cell migration in nonsmall cell lung cancers. J Oncol 2010,
2010:856105.
22. Ling M-T, Wang X, Zhang X, Wong Y-C: The multiple roles of Id-1 in cancer
progression. Differentiation 2006, 74:481–487.
23. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H: The protein Id: a
negative regulator of helix-loop-helix DNA binding proteins. Cell 1990,
61:49–59.
24. Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, Muley T, Meister
M, Hoffmann H, Penzel R, Gdynia G, Ehemann V, Schnabel PA, Kuner R,
Huber P, Schirmacher P, Breuhahn K: Coordinated expression of stathmin
family members by far upstream sequence element-binding protein-1
increases motility in non-small cell lung cancer. Cancer Res 2009,
69:2234–2243.
25. Brito M, Malta-Vacas J, Carmona B, Aires C, Costa P, Martins AP, Ramos S,
Conde AR, Monteiro C: Polyglycine expansions in eRF3/GSPT1 are
associated with gastric cancer susceptibility. Carcinogenesis 2005,
26:2046–2049.
26. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment
search tool. J Mol Biol 1990, 215:403–410.
27. Drews V, Shi K, Haan G, Meisler M: Identification of evolutionarily
conserved, functional noncoding elements in the promoter region of
the sodium channel gene SCN8A. Mamm Genome 2007, 18:723–731.
28. Rubin CI, Atweh GF: The role of stathmin in the regulation of the cell
cycle. J Cell Biochem 2004, 93:242–250.
29. Niethammer P, Bastiaens P, Karsenti E: Stathmin-Tubulin interaction
gradients in motile and mitotic cells. Science 2004, 303:1862–1866.
30. Yeap YYC, Ng IHW, Badrian B, Nguyen TV, Yip YY, Dhillon AS, Mutsaers SE,
Silke J, Bogoyevitch MA, Ng DCH: c-Jun N-terminal kinase/c-Jun inhibits
fibroblast proliferation by negatively regulating the levels of stathmin/
oncoprotein 18. Biochem J 2010, 430:345–354.
31. Ng DCH, Lim CP, Lin BH, Zhang T, Cao X: SCG10-like protein (SCLIP) is a
STAT3-interacting protein involved in maintaining epithelial morphology
in MCF-7 breast cancer cells. Biochem J 2009, 425:95–105.
32. Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P,
Breuhahn K: Protumorigenic overexpression of stathmin/Op18 by
gain-of-function mutation in p53 in human hepatocarcinogenesis.
Hepatology 2007, 46:759–768.
33. Belletti B, Nicoloso MS, Schiappacassi M, Berton S, Lovat F, Wolf K,
Canzonieri V, D'Andrea S, Zucchetto A, Friedl P, Colombatti A, Baldassarre G:
Stathmin activity influences sarcoma cell shape, motility, and metastatic
potential. Mol Biol Cell 2008, 19:2003–2013.
34. Chen G, Wang H, Gharib TG, Huang C-C, Thomas DG, Shedden KA, Kuick R,
Taylor JMG, Kardia SLR, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB,
Hanash SM, Beer DG: Overexpression of Oncoprotein 18 correlates with
poor differentiation in lung Adenocarcinomas. Mol Cell Proteomics 2003,
2:107–116.
35. Kavallaris M, Ng DCH, Byrne F: Stathmin and Cancer, Cytoskeleton and
Human Disease. New York,NY: Humana Press; 2012:259–284.
36. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y,
Kasamatsu A, Shiiba M, Bukawa H, Yokoe H, Tanzawa H: Overexpression of
stathmin in oral squamous-cell carcinoma: correlation with tumour
progression and poor prognosis. Br J Cancer 2006, 94:717–723.
37. Ozawa K, Murakami Y, Eki T, Yokoyama K, Soeda E, Hoshino S-i, Ui M,
Hanaoka F: Mapping of the humanGSPT1 gene, a human homolog of the
Nair et al. Molecular Cancer 2014, 13:173 Page 15 of 15
http://www.molecular-cancer.com/content/13/1/173yeastGST1 gene, to chromosomal band 16p13.1. Somat Cell Mol Genet
1992, 18:189–194.
38. Malta-Vacas J, Ferreira P, Monteiro C, Brito M: Differential expression of
GSPT1 GGCn alleles in cancer. Cancer Genet Cytogenet 2009, 195:132–142.
39. Volkov K, Osipov K, Valouev I, Inge-Vechtomov S, Mironova L: N-terminal
extension of Saccharomyces cerevisiae translation termination factor
eRF3 influences the suppression efficiency of sup35 mutations.
FEMS Yeast Res 2007, 7:357–365.
40. Kodama H, Ito K, Nakamura Y: The role of N-terminal domain of
translational release factor eRF3 for the control of functionality and
stability in S. cerevisiae. Genes Cells 2007, 12:639–650.
41. S-i H, Imai M, Mizutani M, Kikuchi Y, Hanaoka F, Ui M, Katada T: Molecular
cloning of a novel member of the Eukaryotic Polypeptide chain-
releasing factors (eRF): its identification as eRF3 interacting with eRF1.
J Biol Chem 1998, 273:22254–22259.
42. Malta-Vacas J, Aires C, Costa P, Conde AR, Ramos S, Martins AP, Monteiro C,
Brito M: Differential expression of the eukaryotic release factor 3 (eRF3/
GSPT1) according to gastric cancer histological types. J Clin Pathol 2005,
58:621–625.
43. Tallheden T, Karlsson C, Brunner A, van der Lee J, Hagg R, Tommasini R,
Lindahl A: Gene expression during redifferentiation of human articular
chondrocytes. Osteoarthr Cartil 2004, 12:525–535.
44. Wu Y, Zhang X, Salmon M, Zehner ZE: The zinc finger repressor, ZBP-89,
recruits histone deacetylase 1 to repress vimentin gene expression.
Genes Cells 2007, 12:905–918.
45. Zhang CZY, Chen GG, Lai PBS: Transcription factor ZBP-89 in cancer
growth and apoptosis. Biochim Biophys Acta 2010, 1806:36–41.
46. Lee KT, Lee YW, Lee JK, Choi SH, Rhee JC, Paik SS, Kong G: Overexpression
of Id-1 is significantly associated with tumour angiogenesis in human
pancreas cancers. Br J Cancer 2004, 90:1198–1203.
47. Lee TK, Man K, Ling MT, Wang XH, Wong YC, Lo CM, Poon RT, Ng IO,
Fan ST: Over-expression of Id-1 induces cell proliferation in hepatocellular
carcinoma through inactivation of p16INK4a/RB pathway. Carcinogenesis
2003, 24:1729–1736.
48. Benezra R, Rafii S, Lyden D: The Id proteins and angiogenesis. Oncogene
2001, 20:8334–8341.
doi:10.1186/1476-4598-13-173
Cite this article as: Nair et al.: Nicotine-mediated invasion and migration
of non-small cell lung carcinoma cells by modulating STMN3 and GSPT1
genes in an ID1-dependent manner. Molecular Cancer 2014 13:173.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
